Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02376296 · ClinicalTrials.gov registry record

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

A clinical trial of Prostate Cancer, sponsored by Saladax Biomedical.

Completed
Registry status
35
Enrollment target
20
Study locations

NCT02376296 is a study of Prostate Cancer that has completed, run by Saladax Biomedical. The registered enrollment target is 35 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02376296, a study of Prostate Cancer, has completed, sponsored by Saladax Biomedical.

COMPLETED
Registry status
35 participants
Enrollment target
20
Study locations

Study Summary

In this observational study, blood samples for pharmacokinetic (PK) testing will be collected from subjects with metastatic prostate cancer during their treatment with docetaxel. Plasma levels of docetaxel will be determined, and the subjects docetaxel exposure levels, determined as an area under the curve (AUC), will be retrospectively correlated with reports of toxicity, tumor response, quality of life, time to disease progression and overall survival to provide guidance on what the appropriate target range for docetaxel exposure should be for metastatic prostate cancer subjects receiving docetaxel therapy for their disease.

Conditions Studied

Prostate Cancer

Interventions

  • OTHER Blood draws
  • DRUG docetaxel

Study Locations (20)

Pennsylvania

  • UPMC CancerCenter - Beaver - Beaver
  • UPMC CancerCenter - Upper St. Clair - Bethel Park
  • UPMC CancerCenter - Horizon - Farrell
  • Arnold Palmer Cancer Center - Oakbrook - Greensburg
  • Arnold Palmer Cancer Center - Greensburg
  • UPMC CancerCenter - Greenville - Greenville
  • UPMC CancerCenter - Indiana - Indiana
  • UPMC CancerCenter at John P. Murtha Regional Cancer Center - Johnstown
  • UPMC CancerCenter - Mckeesport - McKeesport
  • UPMC CancerCenter - Monroeville - Monroeville
  • Arnold Palmer Medical Oncology - Mount Pleasant - Mount Pleasant
  • UPMC CancerCenter - New Castle - New Castle
  • UPMC CancerCenter - St. Margaret - Pittsburgh
  • UPMC CancerCenter - Hillman Cancer Center - Pittsburgh
  • UPMC CancerCenter - Passavant HOA - Pittsburgh
  • UPMC CancerCenter - Passavant OHA - Pittsburgh
  • UPMC CancerCenter - Northwest - Seneca
  • UPMC CancerCenter - Uniontown - Uniontown
  • UPMC CancerCenter - Washington - Washington
  • UPMC CancerCenter - Jefferson - West Mifflin

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2015-02
Est. Completion 2018-02-10

Sponsor

Saladax Biomedical

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02376296

The ClinicalTrials.gov registry entry for NCT02376296 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Saladax Biomedical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Blood draws is the first listed.

NCT02376296 reports 20 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02376296 about?

NCT02376296 is a clinical study titled "Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients". In this observational study, blood samples for pharmacokinetic (PK) testing will be collected from subjects with metastatic prostate cancer during their treatment with docetaxel. Plasma levels of docetaxel will be determined, and the subjects docetaxel exposure levels, determined as an area under th...

What is the current status of trial NCT02376296?

This trial is currently completed. The enrollment target is 35 participants. The study started on 2015-02. Estimated completion is 2018-02-10.

What conditions does trial NCT02376296 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02376296?

The interventions under investigation include: Blood draws (OTHER), docetaxel (DRUG).

Who is sponsoring clinical trial NCT02376296?

This trial is sponsored by Saladax Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02376296 being conducted?

This trial has 20 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.